Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

AXS-05 Phase II Trial on Smoking Behavior

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03471767
Recruitment Status : Completed
First Posted : March 21, 2018
Last Update Posted : March 19, 2020
Sponsor:
Collaborator:
Axsome Therapeutics, Inc.
Information provided by (Responsible Party):
James Davis, Duke University

Brief Summary:
This research study is designed with the purpose of evaluating a new drug, combination Dextromethorphan-Bupropion (AXS-05), for its effects on smoking behavior.

Condition or disease Intervention/treatment Phase
Smoking Cessation Smoking, Cigarette Nicotine Dependence Drug: AXS-05 Drug: Bupropion SR Phase 2

Detailed Description:

This study aims to investigate the potential efficacy of a combination of two FDA-approved agents, sustained release (SR) Bupropion (BUP) and immediate release (IR) Dextromethorphan (DXM), for the purpose of smoking cessation treatment. DXM, a widely used over-the-counter cough suppressant, is a nicotine receptor antagonist. In fact, studies by Duke's Center for Smoking Cessation (CSC) have shown that administration of DXM leads to a decrease in self-administration of nicotine in nicotine-dependent rats. DXM, however, has not been studied in humans. DXM, when taken alone, is not expected to be useful for treating nicotine dependence in humans given DXM rapidly metabolizes in humans via CYP2D6. As a result, therapeutic concentrations needed to bind to nicotine receptors are not obtained. Therapeutic concentrations of DXM are required, therefore, to allow DXM to bind to nicotine receptors and act as a nicotine antagonist. In order to attain therapeutic concentrations of DXM a metabolism inhibitor must be introduced. BUP is a well-known FDA approved smoking cessation medication that has been shown to inhibit the metabolism of DXM. When BUP is co-administered with DXM to healthy volunteers, a significant increase in DXM plasma levels is observed.

Currently, Axsome Therapeutics Inc. (Axsome) is developing and testing an oral fixed-dose combination of IR DXM with SR BUP to achieve therapeutic concentrations of DXM. This investigational drug has been named AXS-05. Axsome has found AXS-05 to be generally safe and well-tolerated in three Phase 1 studies. The adverse event profile of AXS-05 was similar to that of BUP alone.

Given the distinct mechanisms by which BUP and DXM interact, it is hoped that combining DXM and BUP will prove more efficacious than either drug administered alone for the purpose of tobacco use treatment in humans.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 58 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants are randomized to either take AXS-05 or BUP SR in parallel for the duration of the study.
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind 4-Week Study to Evaluate the Impact of AXS-05 on Smoking Behavior
Actual Study Start Date : March 25, 2018
Actual Primary Completion Date : March 31, 2019
Actual Study Completion Date : March 31, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Smoking

Arm Intervention/treatment
Experimental: AXS-05
Participants will receive AXS-05 (Dextromethorphan Immediate Release + Bupropion Sustained Release) for 4 weeks and will be instructed to take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
Drug: AXS-05
Dextromethorphan Immediate Release + Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
Other Name: Bupropion/dextromethorphan

Active Comparator: Bupropion SR
Participants will receive Bupropion SR (Bupropion Sustained Release) for 4 weeks and will be instructed to take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
Drug: Bupropion SR
Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
Other Names:
  • Wellbutrin SR
  • Zyban SR




Primary Outcome Measures :
  1. Change in Smoking Intensity [ Time Frame: Baseline (V1), 3-Week Follow-Up Visit (V4) ]
    Smoking intensity refers to the total amount of smoke inhaled by the smoker and includes the number of cigarettes smoked per day. Measured through salivary cotinine, expired carbon monoxide (CO) breath testing, and the number of cigarettes smoked per day by composite self-report smoking diaries.


Secondary Outcome Measures :
  1. Change in Smoking Behavior [ Time Frame: 3-Week Follow-Up Visit (V4), 4-Week Follow-Up Visit (V5) ]
    7-day point prevalence smoking abstinence. Measured by composite self-report diaries and biochemically confirmed via expired CO and salivary cotinine.

  2. Medication Adherence [ Time Frame: Baseline (V1), 3-Week Follow-Up Visit (V4) ]
    Medication adherence is measured by composite self-reported diaries.

  3. Medication Tolerance by Self-Reported Side Effects [ Time Frame: Baseline (V1), 3-Week Follow-Up Visit (V4) ]
    Self-reported side effects (open-ended survey questions) with a ranking scale of 1-2 (mild), 3-5 (moderate), 6-7 (severe). Any side effects of 4 or greater will be reviewed by a study medical provider.

  4. Medication Tolerance by Serious Adverse Events [ Time Frame: Baseline (V1), 4-Week Follow-Up Visit (V5) ]
    Measured by FDA reporting guidelines on adverse event or serious adverse event designation.

  5. Urinary Levels of Dextromethorphan [ Time Frame: Baseline (V1), 3-Week Follow-Up Visit (V4) ]
    Measured via Urinary Dextromethorphan testing.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Key Inclusion Criteria:

  1. Age 18 years or above
  2. Daily smoker using 10 or more cigarettes per day
  3. Willing to be smoke-free for 7 days
  4. Is able to provide written informed consent (in English) to participate in the study and able to understand the procedures and study requirements.
  5. Is willing to voluntarily sign and date an informed consent form that is approved by an institutional review board before the conduct of any study procedure.

Key Exclusion Criteria:

  1. Current use of a smoking cessation medication (e.g. nicotine replacement, Varenicline, bupropion)
  2. Current use of tobacco product other than cigarettes (e.g. e-cigarettes, smokeless tobacco)
  3. Not pregnant or breastfeeding
  4. Contraindication to the use of bupropion.
  5. Additional criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03471767


Locations
Layout table for location information
United States, North Carolina
Duke Center for Smoking Cessation
Durham, North Carolina, United States, 27705
Sponsors and Collaborators
James Davis
Axsome Therapeutics, Inc.
Investigators
Layout table for investigator information
Principal Investigator: James M Davis, MD Duke Cancer Institute
Layout table for additonal information
Responsible Party: James Davis, Medical Director, Duke Center for Smoking Cessation, Duke University
ClinicalTrials.gov Identifier: NCT03471767    
Other Study ID Numbers: Pro00089413
First Posted: March 21, 2018    Key Record Dates
Last Update Posted: March 19, 2020
Last Verified: March 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by James Davis, Duke University:
Smoking cessation
Nicotine dependence
Bupropion
DXM
Nicotine addiction
Cigarette smoking
Dextromethorphan
Additional relevant MeSH terms:
Layout table for MeSH terms
Tobacco Use Disorder
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Dextromethorphan
Bupropion
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Antitussive Agents
Respiratory System Agents
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents